SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 6.89 |
| Enterprise Value ($M) | 29.36 |
| Book Value ($M) | -97.62 |
| Book Value / Share | -0.59 |
| Price / Book | -0.07 |
| NCAV ($M) | -97.71 |
| NCAV / Share | -0.59 |
| Price / NCAV | -0.07 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -3.22 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.02 |
| Current Ratio | 0.02 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.81 |
| Assets | 0.90 |
| Liabilities | 98.52 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -3.80 |
| Net Income | -9.48 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -4.18 |
| Cash from Investing | 0.00 |
| Cash from Financing | 3.40 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ayrton Capital LLC | 9.90 | 2.43 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,265,408 | 3,873,422 | 32.67 | |
| 2,810,909 | 7,836,889 | 35.87 | |
| 2,454,807 | 6,339,395 | 38.72 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NRSN – NeuroSense Therapeutics Ltd. | NRXP – NRx Pharmaceuticals, Inc. |
| NVCT – Nuvectis Pharma, Inc. | OCGN – Ocugen, Inc. |
| OCX – OncoCyte Corporation |
Financial data and stock pages provided by
Fintel.io